Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sara West

Psychiatry Akron, OH Medical Doctor

NPI 1639382062 CMS profile 865067

Community Support Services, INC, 150 Cross Street, Akron, OH 44311

Open in the dashboard

General payments

$8,391

468 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sara West of Akron, OH is reported in the CMS Open Payments database as having received $8,391 across 468 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,644 106
2024 General $1,662 122
2023 General $2,019 120
2022 General $1,102 49
2021 General $1,455 61
2020 General $238 4
2019 General $270 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sara West
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Sara West were reported at $1,644. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Sara West Psychiatry median Middle half National median
2019 $270 $184 $59–$605 $163
2020 $238 $119 $36–$372 $114
2021 $1,455 $143 $43–$576 $132
2022 $1,102 $153 $50–$590 $149
2023 $2,019 $170 $56–$651 $160
2024 $1,662 $179 $57–$673 $164
2025 $1,644 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $1,694 72 payments
  2. Alkermes, Inc. $1,269 55 payments
  3. ITI, Inc. $1,178 93 payments
  4. Otsuka America Pharmaceutical, Inc. $1,017 48 payments
  5. Lundbeck LLC $822 48 payments
  6. AbbVie, Inc. $607 36 payments
  7. Teva Pharmaceuticals USA, Inc. $589 52 payments
  8. Neurocrine Biosciences, Inc. $519 32 payments
  9. E.R. Squibb & Sons, L.L.C. $260 10 payments
  10. Vanda Pharmaceuticals Inc. $170 6 payments
  11. Other $265 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,351 466 payments
  2. Education $39 2 payments
Products named General payments · program years 2019–2025
  1. INVEGA SUSTENNA $1,333 66 payments
  2. ARISTADA Cns $1,123 53 payments
  3. ARISTADA Cns $1,123 53 payments
  4. ABILIFY MAINTENA $1,063 61 payments
  5. ARISTADA Cns $967 44 payments
  6. ARISTADA Cns $967 44 payments
  7. CAPLYTA $919 72 payments
  8. LYBALVI $910 46 payments
  9. INVEGA TRINZA $596 20 payments
  10. VRAYLAR $589 35 payments
  11. Other $4,418 222 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 49 drugs

Part D claims

2,396

Median for Psychiatry: 574

Drug cost

$1,464,545

Median for Psychiatry: $27,624

Branded share of claims

27%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 201 $555,962
Invega Trinza Paliperidone Palmitate Brand 38 $307,425
Invega Hafyera Paliperidone Palmitate Brand 13 $211,203
Abilify Asimtufii Aripiprazole Brand 27 $122,595
Ingrezza Valbenazine Tosylate Brand 11 $88,509
Abilify Maintena Aripiprazole Brand 22 $48,076
Aristada Aripiprazole Lauroxil Brand 12 $44,573
Vivitrol Naltrexone Microspheres Brand 15 $23,233
Vraylar Cariprazine Hcl Brand 14 $19,953
Clozapine Generic 271 $15,577

The 10 drugs with the highest cost, of 49 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $271
$271 — —
ABILIFY MAINTENA
  • Lundbeck LLC $176
  • Otsuka America Pharmaceutical, Inc. $8
$184 22 —
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $177
$177 201 —
COBENFY
  • E.R. Squibb & Sons, L.L.C. $177
$177 — —
ARISTADA
  • Alkermes, Inc. $151
$151 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

468 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record